Lieu de naissance
ARALIK
Langues
İNGİLİZCE
Expériences
2024 - 2025
İstinye Üniversitesi Bahçeşehir Hastanesi
2019 - 2024
Van Bölge Eğitim ve Araştırma Hastanesi
2014 - 2014
Silopi Devlet Hastanesi
2007 - 2008
Van Devlet Hastanesi
Éducation
2018
İstanbul Üniversitesi İstanbul Tıp Fakültesi, Romatoloji
2014
İstanbul Üniversitesi İstanbul Tıp Fakültesi, İç Hastalıkları
2014
İstanbul Üniversitesi İstanbul Tıp Fakültesi, İç Hastalıkalrı
2010
Atatürk Üniversitesi Tıp Fakültesi, Kardiyoloji -Araştırma Görevlisi
2007
Uludağ Üniversitesi, Tıp Fakültesi
Publications
1. Oğuz E, Bektaş M. Characteristics of patients with Behçet disease from the Van province, eastern Turkey: Definition of disease clusters in a tertiary referral center. J Clin Rheumatol. 2023. doi:10.1097/RHU.0000000000001996
2. Oğuz E, et al. Characteristics and course of patients with AA amyloidosis: Single centre experience with 174 patients from Turkey. Rheumatology (Oxford). 2024;63(2):319-328. doi:10.1093/rheumatology/kead465
3. Oğuz E, et al. Utility of positron emission tomography as a new tool for muscle involvement in patients with idiopathic inflammatory myositis: A controlled study. Clin Exp Rheumatol. 2024;42(2):358-366. doi:10.55563/clinexprheumatol/9u122p
4. Bektaş M, Özer MD, Oğuz E. The safety and efficacy of TNF inhibitors in patients with Behçet’s disease: Retrospective study from eastern Turkey. Clin Immunol. 2024;264:110239. doi:10.1016/j.clim.2024.110239
5. Oğuz E, Koca N, Bektaş M. Presence of myositis-specific autoantibodies may predict favorable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study. Mod Rheumatol. 2025 (ahead of print). doi:10.1093/mr/roaf097
6. Oğuz E, et al. Chronic oxcarbazepine intoxication in a patient with primary antiphospholipid syndrome on maintenance haemodialysis. J Clin Pharm Ther. 2022;47(2):257-259. doi:10.1111/jcpt.13504
7. Oğuz E, et al. Activation-induced cytidine deaminase expression in patients with chronic myeloid leukemia Experimed. 2022;12(3):155-159
8. Oğuz E, et al. Üçüncü basamak bir hastanede takip edilen COVID-19 olgularında immünosüpresif tedavi uygulanan hastaların değerlendirilmesi. Klimik Dergisi. 2022
ULUSLARARASI KONGRE SUNUMLARI (ACR)
9. Oğuz E, et al. Classification of idiopathic inflammatory myopathies: Assessment according to 2017 ACR/EULAR criteria. Arthritis Rheumatol. 2018;70(Suppl 9)
10. Oğuz E, et al. Favourable response to rituximab in IgG4-related disease: Long-term follow-up. Arthritis Rheumatol. 2018;70(Suppl 9)
11. Bektaş M, et al., Oğuz E. PET imaging in idiopathic inflammatory myositis: A case-control study. Arthritis Rheumatol. 2021;73(Suppl 9)
12. Toz B, et al., Oğuz E. IL-1 inhibitors in FMF-associated amyloidosis: Retrospective analysis. Arthritis Rheumatol. 2016;68(Suppl 10